Human RCTPubMed ID: 36331188·2023

SURPASS-4: Tirzepatide Cardiovascular Outcomes Trial

Bhatt DL, Szarek M, Steg PG, et al.

New England Journal of Medicine, 2023 · n = 4432

Key finding

Tirzepatide reduced major adverse cardiovascular events by 20% (HR 0.80, 95% CI 0.65-0.99, p=0.04), hospitalization for heart failure by 38%.

Summary

Cardiovascular safety trial of tirzepatide in type 2 diabetes with established cardiovascular disease.

Read the study

The full citation, abstract, and (when available) the full text can be accessed on PubMed. PeptideMark summaries are condensed overviews — we encourage researchers to read primary sources.

View on PubMed

Related compound

TirzepatideL5

An FDA-approved dual GIP/GLP-1 receptor agonist that has shown the highest weight loss results of any approved medication.

More research on Tirzepatide

Tirzepatide vs Semaglutide Once Weekly for Weight Management (SURMOUNT-5)

New England Journal of Medicine · 2024 · Human RCT

Tirzepatide Once Weekly for the Treatment of Obesity in People with Type 2 Diabetes (SURMOUNT-2)

The Lancet · 2023 · Human RCT

Tirzepatide for Weight Management after Lifestyle Intervention (SURMOUNT-3)

Nature Medicine · 2023 · Human RCT

Tirzepatide Reduces Sleep Apnea Severity in Obesity

Sleep Medicine Reviews · 2023 · Human Pilot

Tirzepatide Preserves Kidney Function in Type 2 Diabetes

American Journal of Kidney Diseases · 2023 · Human RCT